Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | OXTR | P30559 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170816 | 0.84 | OXTR (0.52) | MAOAMAOBOXTRABCG2HSD17B3 | |
| SCHEMBL346944 | 0.84 | — | — | |
| SCHEMBL30349594 | 0.84 | — | — | |
| SCHEMBL7466845 | 0.82 | ABCG2 (0.65) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL28675786 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL8863598 | 0.81 | — | — | |
| Bromide SCHEMBL22498666 | 0.81 | — | — | |
| SCHEMBL10253863 | 0.80 | OXTR (0.45) | MAOAMAOBOXTRABCG2HSD17B3 | |
| Hydrochloric Acid SCHEMBL8131892 | 0.79 | OXTR (0.48) | MAOAMAOBOXTRABCG2HSD17B3 | |
| SCHEMBL31427012 | 0.79 | MAOA (0.94) | MAOAMAOBOXTRABCG2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| JP-2008508314-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1778242-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015259-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | claimed |
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | claimed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | claimed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | claimed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| CN-116239562-B | Method for synthesizing doxepin hydrochloride by taking benzofuranone as raw material | 江苏师范大学 | 2024-12-31 | — | — | CN | disclosed |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2024-09-12 | — | — | US | disclosed |
| EP-4333821-A1 | INHIBITORS OF SARS-COV-2 | The Texas A&M University System (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333821-A1 | INHIBITORS OF SARS-COV-2 | The Texas A&M University System (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0038564-A1 | Dibenz (b,e) oxepin derivatives and pharmaceutical compositions comprising them | KYOWA HAKKO KOGYO CO., LTD (JP) | 1981-10-28 | — | — | EP | disclosed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4169205-A | BACTERICIDES; FUNGICIDES | E. R. SQUIBB & SONS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4169205-A | BACTERICIDES; FUNGICIDES | E. R. SQUIBB & SONS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4169205-A | BACTERICIDES; FUNGICIDES | E. R. SQUIBB & SONS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | ACE2, ACE, TMPRSS2 | MAOA 1116/4885MAOB 1253/4885OXTR 2584/4885 |
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | MAOA 4482/4885MAOB 4509/4885OXTR 752/4885 |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | DAO, DNPEP, DDO | MAOA 365/4885MAOB 263/4885OXTR 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.